# Get a FirstLook at Lung Cancer Lung cancer can be found early, but 84% of eligible adults are not getting the nationally recommended LDCT screening. Overcome lung cancer screening barriers with an easy first step. Imagine lung cancer screening as easy as a routine blood draw. --- ## An Innovation in Lung Cancer Screening The new FirstLook blood test offers a convenient, accessible approach to enhance lung cancer screening. FirstLook helps determine the likelihood of detecting lung cancer through low-dose CT (LDCT). ### Addressing Your Screening Challenge Lung cancer screening faces unique barriers - patient anxiety about radiation and scheduling difficulties for LDCT. FirstLook addresses these barriers by offering the first step as a simple blood draw during routine visits. FirstLook Lung is a next-generation sequencing laboratory-developed test (LDT) of plasma-cell-free DNA that analyzes DNA fragment sizes in blood to indicate the possible presence of lung cancer. ### Seamless Practice Integration Like other routine blood draws, FirstLook can be completed in your office or by your institution's phlebotomy lab. No special equipment, no patient prep, and results delivered in 10-14 days. Lung cancer screening has fallen behind other cancer screenings. Due to a lack of screening, lung cancer is the number one cause of cancer-related deaths, claiming more lives than colon, breast, and cervical cancers combined. #### Screening Rates: Eligible US Adults Using FirstLook Lung to improve screening uptake aligns with CDC/HHS Healthy People 2030 Objectives. --- ### Understand Your Patient's Lung Health at a Glance FirstLook provides binary results: - **An Elevated result** means a higher likelihood of lung cancer detected by low-dose CT (LDCT). - **A Not Elevated result** suggests a lower likelihood that LDCT will detect lung cancer. FirstLook was validated in a prospective, case-controlled, observational study. #### Clinically Impactful Performance - **99.8% NPV**: In individuals with a Not Elevated result, the chance of detecting lung cancer by LDCT is 2 in 1000. - **79 NNS**: About 79 people with an Elevated result need an LDCT to find one person with lung cancer compared with an NNS of 143 for anyone screen eligible. - **5.2X RR**: The likelihood of a lung cancer being found by LDCT for individuals with an Elevated result is 5.2 times as high as for those with a Not Elevated result. ### Provider Support You Can Count On NNS: Number needed to screen, NPV: Negative predictive value, RR: Relative risk. - Results interpretation support and clinical consultation available. It’s time to take a FirstLook at lung cancer. Get your patients tested today. FirstLook supports lung cancer screening decisions across age groups. The blood test provides additional risk stratification information to help guide LDCT screening decisions. ### Clinical Integration An elevated result indicates a higher likelihood that LDCT will be productive and is the next best step for the patient, while a not elevated result can help inform shared decision-making about screening timing. --- # Coverage & Reimbursement FirstLook is a laboratory-developed test. Our team works with you and your patients to verify benefits and explore coverage options. ## Workflow Steps: - **Test order & support**: Blood draw, Return of results, Results support - Accessible ordering, Routine blood collection, Simple binary results delivered to facilitate informed decisions and follow-up. ### Contact Information Contact DELFI Diagnostics Client Services for questions about accessing the provider portal and ordering FirstLook Lung. Visit us online to learn more about the FirstLook Lung test. - **1-800-589-2182** - **clientservices@delfidiagnostics.com** **Indications for Use Laboratory Information**: FirstLook is indicated as an adjunct assessment tool for individuals (50-80 years of age, 20 pack-years of smoking, currently smoking or has quit within 15 years). The FirstLook Lung test is a laboratory-developed test. This test was developed, and its performance deemed as high risk by the USPSTF and eligible for lung cancer screening characteristics were determined by DELFI Diagnostics. It has not been cleared or approved by the US Food and Drug Administration (FDA). The laboratory is regulated under the Clinical Laboratory Improvement Act (CLIA) as qualified to perform high-complexity clinical tests. The test is used for clinical purposes. It should not be regarded as investigational or for research. **References:** 1. State of Lung Cancer | Key Findings | American Lung Association. Accessed December 21, 2024. 2. Wang GX et al. Barriers to lung cancer screening engagement from the patient and provider perspective. Radiology. 2019;290(2):278-287. 3. Meza R et al. Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: modeling study for the US Preventive Services Task Force. JAMA. 2021;325(10):988-997. 4. NIH National Cancer Institute. CancerStat Facts: Common Cancer Sites. 2023. 5. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2023-2024. 6. Cancer-Healthy People 2030 | health.gov. [https://health.gov/healthypeople/objectives-and-data/browse-objectives/cancer](https://health.gov/healthypeople/objectives-and-data/browse-objectives/cancer). 7. National Lung Screening Trial Research Team; Aberle DR et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. 8. de Koning HJ et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(5):311-320. 9. Unpublished data on file. 10. Bach PB et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95(6):470-478.